A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Public ClinicalTrials.gov record NCT03661320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Study identification
- NCT ID
- NCT03661320
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 855 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2018 (Actual)
- Primary completion
- Feb 16, 2026 (Actual)
- Completion
- Apr 14, 2026 (Actual)
- Last update posted
- Sep 10, 2026
2018 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0022 | Tucson | Arizona | 85711 | — |
| UC Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| Local Institution - 0021 | Littleton | Colorado | 80120-4413 | — |
| Local Institution - 0036 | Pensacola | Florida | 32503 | — |
| Local Institution - 0004 | Tampa | Florida | 33612 | — |
| Local Institution - 0144 | Atlanta | Georgia | 30342 | — |
| Local Institution - 0005 | Chicago | Illinois | 60637 | — |
| Local Institution - 0006 | Peoria | Illinois | 61615 | — |
| Local Institution - 0181 | Columbia | Maryland | 21044 | — |
| Local Institution - 0009 | Boston | Massachusetts | 02114 | — |
| Local Institution - 0166 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0209 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0025 | Minneapolis | Minnesota | 55404 | — |
| Local Institution - 0129 | Minneapolis | Minnesota | 55455 | — |
| Local Institution - 0183 | Omaha | Nebraska | 68130 | — |
| Local Institution - 0001 | Omaha | Nebraska | 68198-6840 | — |
| Local Institution - 0024 | Las Vegas | Nevada | 89169 | — |
| Local Institution - 0029 | Albany | New York | 12208 | — |
| Local Institution - 0069 | Lake Success | New York | 11042 | — |
| Local Institution - 0047 | New York | New York | 10065 | — |
| Local Institution - 0191 | Cleveland | Ohio | 44195 | — |
| Local Institution - 0028 | Tigard | Oregon | 97223 | — |
| Local Institution - 0189 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0007 | Nashville | Tennessee | 37232 | — |
| Local Institution - 0030 | Austin | Texas | 78731 | — |
| Local Institution - 0023 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 146 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03661320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03661320 live on ClinicalTrials.gov.